OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
14 feb 2007 - 23:38
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces 2006 annual results
Bericht
OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO), the drug delivery and development company, announces today its annual results for the year ended 31 December 2006.
Highlights 2006
2 development-stage products progressed to Phase II clinical studies: Locteron, for the treatment of chronic hepatitis C, and OP-145 for the treatment of chronic middle ear infection
Contract Development revenues increased 25%
IPO on Euronext Amsterdam generated € 20 million (gross) in new capital
Gerelateerde downloads
Datum laatste update: 01 september 2024